Corvus Pharmaceuticals, Inc. (CRVS) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
863 MITTEN ROAD BURLINGAME, CA 94010 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments, including: | 69,500 | 44,300 | 78,000 | 114,600 | 90,100 | 134,900 | ||
| Cash and cash equivalents | 63,458 | 16,455 | 5,154 | 39,196 | 45,106 | 5,050 | ||
| Other undisclosed cash, cash equivalents, and short-term investments | 6,042 | 27,845 | 72,846 | 75,404 | 44,994 | 129,850 | ||
| Receivables | 507 | |||||||
| Prepaid expense | 280 | 244 | 150 | 166 | ||||
| Other current assets | 128 | 406 | 486 | 265 | 720 | 772 | ||
| Other undisclosed current assets | 897 | 386 | 708 | 558 | 414 | 361 | ||
| Total current assets: | 71,312 | 45,336 | 79,344 | 115,589 | 91,234 | 136,033 | ||
| Noncurrent Assets | ||||||||
| Operating lease, right-of-use asset | 3,190 | 1,648 | 2,327 | ✕ | ✕ | ✕ | ||
| Property, plant and equipment | 451 | 906 | 1,462 | 2,180 | 2,672 | 3,248 | ||
| Long-term investments and receivables | 34,266 | 37,225 | ||||||
| Long-term investments | 34,266 | 37,225 | ||||||
| Other noncurrent assets | 236 | 414 | 513 | 463 | 869 | 869 | ||
| Total noncurrent assets: | 38,143 | 40,193 | 4,302 | 2,643 | 3,541 | 4,117 | ||
| TOTAL ASSETS: | 109,455 | 85,529 | 83,646 | 118,232 | 94,775 | 140,150 | ||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 3,797 | 6,069 | 4,351 | 3,072 | 4,633 | 2,994 | ||
| Accounts payable | 1,565 | 3,467 | 2,448 | 1,998 | 3,454 | 1,900 | ||
| Accrued liabilities | 386 | 377 | 279 | 425 | 607 | 568 | ||
| Employee-related liabilities | 1,846 | 2,225 | 1,624 | 649 | 572 | 526 | ||
| Debt | 878 | |||||||
| Deferred rent credit | 160 | ✕ | ✕ | |||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | 410 | 378 | ||
| Other undisclosed current liabilities | 5,895 | 6,080 | 4,996 | 3,795 | 3,926 | 2,572 | ||
| Total current liabilities: | 9,692 | 12,149 | 10,225 | 7,027 | 8,969 | 5,944 | ||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 2,601 | 1,232 | 2,310 | |||||
| Operating lease, liability | 2,601 | 1,232 | 2,310 | ✕ | ✕ | ✕ | ||
| Liabilities, other than long-term debt | 869 | 971 | 1,405 | |||||
| Other liabilities | 869 | 971 | 1,405 | |||||
| Other undisclosed noncurrent liabilities | (2,601) | (1,232) | ||||||
| Total noncurrent liabilities: | 2,601 | 1,232 | 2,310 | 869 | 971 | 1,405 | ||
| Total liabilities: | 12,293 | 13,381 | 12,535 | 7,896 | 9,940 | 7,349 | ||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent | 97,162 | 72,148 | 71,111 | 110,336 | 84,835 | 132,801 | ||
| Common stock | 5 | 3 | 3 | 3 | 2 | 2 | ||
| Additional paid in capital | 361,669 | 295,281 | 288,224 | 280,840 | 208,408 | 200,709 | ||
| Accumulated other comprehensive income (loss) | 1,869 | 4 | 29 | (34) | (41) | (39) | ||
| Accumulated deficit | (266,381) | (223,140) | (217,145) | (170,473) | (123,534) | (67,871) | ||
| Total stockholders' equity: | 97,162 | 72,148 | 71,111 | 110,336 | 84,835 | 132,801 | ||
| TOTAL LIABILITIES AND EQUITY: | 109,455 | 85,529 | 83,646 | 118,232 | 94,775 | 140,150 | ||
Income Statement (P&L) ($ in thousands) Annual | Quarterly
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | ||
|---|---|---|---|---|---|---|---|
| Operating expenses | (38,630) | (43,760) | (48,854) | (49,222) | (56,524) | (36,976) | |
| Other undisclosed operating income | 4,831 | 234 | |||||
| Operating loss: | (38,630) | (43,760) | (48,854) | (49,222) | (56,524) | (36,976) | |
| Nonoperating income (Investment Income, Nonoperating) | 37,459 | ||||||
| Loss from continuing operations before equity method investments, income taxes: | (38,630) | (6,301) | (48,854) | (49,222) | (56,524) | (36,976) | |
| Other undisclosed income (loss) from continuing operations before income taxes | (4,611) | 306 | 2,182 | 2,283 | 861 | 601 | |
| Net loss available to common stockholders, diluted: | (43,241) | (5,995) | (46,672) | (46,939) | (55,663) | (36,375) | |
Comprehensive Income ($ in thousands)Annual | Quarterly
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (43,241) | (5,995) | (46,672) | (46,939) | (55,663) | (36,375) | |
| Comprehensive loss: | (43,241) | (5,995) | (46,672) | (46,939) | (55,663) | (36,375) | |
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 1,865 | (25) | 63 | 7 | (2) | 6 | |
| Comprehensive loss, net of tax, attributable to parent: | (41,376) | (6,020) | (46,609) | (46,932) | (55,665) | (36,369) | |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.